<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339452</url>
  </required_header>
  <id_info>
    <org_study_id>37481</org_study_id>
    <nct_id>NCT04339452</nct_id>
  </id_info>
  <brief_title>Impella Supported OPCABG</brief_title>
  <official_title>Impella-supported Off-pump Coronary Artery Bypass Grafting in High Risk Revascularizations: A Single Center Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Joyce, MD, MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study introduces a novel approach to coronary revascularization through the use&#xD;
      of a short term minimally-invasive LVAD to minimize myocardial injury and eliminate low&#xD;
      output state during the perioperative period&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative hemodynamic stability</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative hemodynamic stability, defined as mean arterial pressure (MAP), cardiac index (CI), central venous pressure (CVP), and cerebral perfusion as measured by NIRS maintained within normal ranges for the entire operative time except potentially for short periods not exceeding 10 minutes in total time.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG</intervention_name>
    <description>Subjects will undergo insertion of an axillary or ascending aortic Impella 5.0 Device or Impella 5.5 with SmartAssist, followed by Impella supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients fitting inclusion criteria will undergo Impella supported OPCABG using coronary&#xD;
        shunts. Inclusion criteria will target patients with ischemic cardiomyopathy, similarly&#xD;
        defined to the STICH trial which evaluated coronary revascularization in the setting of&#xD;
        heart failure (defined by an EF≤35%). Patients would be considered for enrollment in the&#xD;
        setting of symptomatic severe multi-vessel coronary artery disease with target vessels that&#xD;
        are amenable to bypass (as determined by the operating surgeon).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Ejection fraction ≤ 35%&#xD;
&#xD;
          -  Symptomatic three vessel Coronary Artery Disease with target vessels that are amenable&#xD;
             to bypass (as determined by the operating surgeon)&#xD;
&#xD;
          -  Adequate Distal target caliber (as determined by the PI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria will include the existing contraindications to either Impella&#xD;
             therapy or OPCABG revascularization:&#xD;
&#xD;
               -  Patients with structural heart disease requiring CPB&#xD;
&#xD;
               -  Patients with cardiogenic shock who require a period of short-term MCS&#xD;
&#xD;
               -  Patients with mechanical aortic valve&#xD;
&#xD;
               -  Patients with previous median sternotomy&#xD;
&#xD;
               -  Patients with evidence of non-viability on preoperative cardiac MRI or CT scan&#xD;
&#xD;
               -  Insufficient conduit&#xD;
&#xD;
               -  BMI over 50&#xD;
&#xD;
               -  Patients who are COVID-19 positive at the time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Joyce, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krissa Packard, MS</last_name>
    <phone>4149551861</phone>
    <email>kpackard@mcw.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>David Joyce, MD, MBA</investigator_full_name>
    <investigator_title>David Joyce, MD, MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

